Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Using Image-guided Intensity-modulated Radiotherapy on Patients With Head and Neck Soft-tissue Sarcoma.

Elsayad K, Stockmann D, Channaoui M, Scobioala S, Grajda A, Berssenbrügge H, Huss S, Moustakis C, Haverkamp U, Kleinheinz J, Lenz G, Wardelmann E, Eich HT.

In Vivo. 2019 Jul-Aug;33(4):1293-1300. doi: 10.21873/invivo.11602.

PMID:
31280221
2.

Exogenous expression of caveolin-1 is sufficient for hepatic stellate cell activation.

Ilha M, Moraes KDS, Rohden F, Martins LAM, Borojevic R, Lenz G, Barbé-Tuana F, Guma FCR.

J Cell Biochem. 2019 Jun 30. doi: 10.1002/jcb.29226. [Epub ahead of print]

PMID:
31257611
3.

Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells.

Thomé MP, Pereira LC, Onzi GR, Rohden F, Ilha M, Guma FT, Wink MR, Lenz G.

Exp Cell Res. 2019 Jun 11. pii: S0014-4827(19)30288-5. doi: 10.1016/j.yexcr.2019.06.001. [Epub ahead of print]

PMID:
31194978
4.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0505-x. [Epub ahead of print]

PMID:
31182782
5.

Characterization of soluble CD39 (SolCD39/NTPDase1) from PiggyBac nonviral system as a tool to control the nucleotides level.

Beckenkamp LR, Iser IC, Onzi GR, Fontoura DMSD, Bertoni APS, Sévigny J, Lenz G, Wink MR.

Biochem J. 2019 Jun 11;476(11):1637-1651. doi: 10.1042/BCJ20190040.

PMID:
31085558
6.

Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma.

Oertel M, Elsayad K, Kroeger KJ, Haverkamp U, Rudack C, Lenz G, Eich HT.

Radiat Oncol. 2019 Apr 15;14(1):63. doi: 10.1186/s13014-019-1265-5.

7.

PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice.

Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, Strong A, Pfaus A, Friedrich MJ, Engleitner T, Lersch R, Öllinger R, Grau M, Menendez IG, Martella M, Kohlhofer U, Banerjee R, Turchaninova MA, Scherger A, Hoffman GJ, Hess J, Kuhn LB, Ammon T, Kim J, Schneider G, Unger K, Zimber-Strobl U, Heikenwälder M, Schmidt-Supprian M, Yang F, Saur D, Liu P, Steiger K, Chudakov DM, Lenz G, Quintanilla-Martinez L, Keller U, Vassiliou GS, Cadiñanos J, Bradley A, Rad R.

Nat Commun. 2019 Mar 29;10(1):1415. doi: 10.1038/s41467-019-09180-3.

8.

Safeguard function of PU.1 shapes the inflammatory epigenome of neutrophils.

Fischer J, Walter C, Tönges A, Aleth H, Jordão MJC, Leddin M, Gröning V, Erdmann T, Lenz G, Roth J, Vogl T, Prinz M, Dugas M, Jacobsen ID, Rosenbauer F.

Nat Immunol. 2019 May;20(5):546-558. doi: 10.1038/s41590-019-0343-z. Epub 2019 Mar 25.

PMID:
30911105
9.

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).

Kessler T, Koschmieder S, Schliemann C, Crysandt M, Mikesch JH, von Stillfried S, Stelljes M, Pohlen M, Lenz G, Kirsch A, Vehring K, Wardelmann E, Hartmann W, Bormann E, Gerss J, Brümmendorf TH, Müller-Tidow C, Berdel WE.

Ann Hematol. 2019 Jun;98(6):1393-1401. doi: 10.1007/s00277-019-03651-9. Epub 2019 Mar 21.

PMID:
30903275
10.

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas.

Gonçalves RM, Agnes JP, Delgobo M, de Souza PO, Thomé MP, Heimfarth L, Lenz G, Moreira JCF, Zanotto-Filho A.

Biochem Pharmacol. 2019 May;163:440-450. doi: 10.1016/j.bcp.2019.03.015. Epub 2019 Mar 13.

PMID:
30878553
11.

Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT.

Strahlenther Onkol. 2019 Jun;195(6):544-557. doi: 10.1007/s00066-019-01446-5. Epub 2019 Mar 11.

PMID:
30859254
12.

Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging.

Nunes TWN, Filippi-Chiela EC, Callegari-Jacques SM, da Silva VD, Sansonowicz T, Lenz G, Roehe AV.

Melanoma Res. 2019 Mar 4. doi: 10.1097/CMR.0000000000000594. [Epub ahead of print]

PMID:
30839356
13.

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):135-141. doi: 10.1016/j.clml.2018.11.021. Epub 2018 Nov 29.

14.

esiCancer: Evolutionary In Silico Cancer Simulator.

Minussi DC, Henz B, Dos Santos Oliveira M, Filippi-Chiela EC, Oliveira MM, Lenz G.

Cancer Res. 2019 Mar 1;79(5):1010-1013. doi: 10.1158/0008-5472.CAN-17-3924. Epub 2018 Dec 18.

PMID:
30563892
15.

Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.

Avanes A, Lenz G, Momand J.

Biochem Pharmacol. 2019 Feb;160:71-79. doi: 10.1016/j.bcp.2018.12.008. Epub 2018 Dec 12. Review.

PMID:
30552871
16.

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group.

Br J Haematol. 2019 Mar;184(5):760-768. doi: 10.1111/bjh.15710. Epub 2018 Dec 5.

PMID:
30520013
17.

Chromatin conformation analysis of primary patient tissue using a low input Hi-C method.

Díaz N, Kruse K, Erdmann T, Staiger AM, Ott G, Lenz G, Vaquerizas JM.

Nat Commun. 2018 Nov 29;9(1):4938. doi: 10.1038/s41467-018-06961-0.

18.

EMT-like process in glioblastomas and reactive astrocytes.

Iser IC, Lenz G, Wink MR.

Neurochem Int. 2019 Jan;122:139-143. doi: 10.1016/j.neuint.2018.11.016. Epub 2018 Nov 26.

PMID:
30496766
19.

Temporal autoregulation during human PU.1 locus SubTAD formation.

Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F.

Blood. 2018 Dec 20;132(25):2643-2655. doi: 10.1182/blood-2018-02-834721. Epub 2018 Oct 12.

PMID:
30315124
20.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

21.

FHIRChain: Applying Blockchain to Securely and Scalably Share Clinical Data.

Zhang P, White J, Schmidt DC, Lenz G, Rosenbloom ST.

Comput Struct Biotechnol J. 2018 Jul 29;16:267-278. doi: 10.1016/j.csbj.2018.07.004. eCollection 2018.

22.

A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality.

Daigle TL, Madisen L, Hage TA, Valley MT, Knoblich U, Larsen RS, Takeno MM, Huang L, Gu H, Larsen R, Mills M, Bosma-Moody A, Siverts LA, Walker M, Graybuck LT, Yao Z, Fong O, Nguyen TN, Garren E, Lenz GH, Chavarha M, Pendergraft J, Harrington J, Hirokawa KE, Harris JA, Nicovich PR, McGraw MJ, Ollerenshaw DR, Smith KA, Baker CA, Ting JT, Sunkin SM, Lecoq J, Lin MZ, Boyden ES, Murphy GJ, da Costa NM, Waters J, Li L, Tasic B, Zeng H.

Cell. 2018 Jul 12;174(2):465-480.e22. doi: 10.1016/j.cell.2018.06.035.

23.

90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience.

Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A.

Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.

PMID:
29993147
24.

Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.

Pereira MB, Barros LRC, Bracco PA, Vigo A, Boroni M, Bonamino MH, Lenz G.

Oncoimmunology. 2018 Feb 12;7(6):e1431083. doi: 10.1080/2162402X.2018.1431083. eCollection 2018.

25.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
26.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

27.

Autophagy in glioma cells: An identity crisis with a clinical perspective.

Ulasov IV, Lenz G, Lesniak MS.

Cancer Lett. 2018 Aug 1;428:139-146. doi: 10.1016/j.canlet.2018.04.034. Epub 2018 Apr 27.

PMID:
29709703
28.

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.

Schmitz N, Lenz G, Stelljes M.

Blood. 2018 Jul 19;132(3):245-253. doi: 10.1182/blood-2018-01-791335. Epub 2018 Apr 26. Review.

PMID:
29699989
29.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.

30.

Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.

Dunleavy K, Erdmann T, Lenz G.

Cancer Treat Rev. 2018 Apr;65:41-46. doi: 10.1016/j.ctrv.2018.01.002. Epub 2018 Feb 1. Review.

PMID:
29549872
31.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
32.

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.

Gu JJ, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ.

Oncotarget. 2017 Dec 19;9(3):4020-4033. doi: 10.18632/oncotarget.23425. eCollection 2018 Jan 9.

33.

The developing human connectome project: A minimal processing pipeline for neonatal cortical surface reconstruction.

Makropoulos A, Robinson EC, Schuh A, Wright R, Fitzgibbon S, Bozek J, Counsell SJ, Steinweg J, Vecchiato K, Passerat-Palmbach J, Lenz G, Mortari F, Tenev T, Duff EP, Bastiani M, Cordero-Grande L, Hughes E, Tusor N, Tournier JD, Hutter J, Price AN, Teixeira RPAG, Murgasova M, Victor S, Kelly C, Rutherford MA, Smith SM, Edwards AD, Hajnal JV, Jenkinson M, Rueckert D.

Neuroimage. 2018 Jun;173:88-112. doi: 10.1016/j.neuroimage.2018.01.054. Epub 2018 Jan 31.

34.

Analysis of NTPDase2 in the cell membrane using fluorescence recovery after photobleaching (FRAP).

Kipper FC, Tamajusuku ASK, Minussi DC, Vargas JE, Battastini AMO, Kaczmarek E, Robson SC, Lenz G, Wink MR.

Cytometry A. 2018 Feb;93(2):232-238. doi: 10.1002/cyto.a.23317. Epub 2018 Jan 24.

35.

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O.

Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. Review.

PMID:
29359797
36.

Evolution of a designed protein assembly encapsulating its own RNA genome.

Butterfield GL, Lajoie MJ, Gustafson HH, Sellers DL, Nattermann U, Ellis D, Bale JB, Ke S, Lenz GH, Yehdego A, Ravichandran R, Pun SH, King NP, Baker D.

Nature. 2017 Dec 21;552(7685):415-420. doi: 10.1038/nature25157. Epub 2017 Dec 13.

37.

t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.

Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, Kane SE, Huss JM.

Clin Cancer Res. 2018 Mar 1;24(5):1216-1226. doi: 10.1158/1078-0432.CCR-17-0824. Epub 2017 Nov 27.

38.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
39.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

40.

Individualisierte Therapie des metastasierten Lungenkarzinoms.

Evers G, Mohr M, Kerkhoff A, Lenz G, Wiewrodt R, Schmidt LH.

Dtsch Med Wochenschr. 2017 Oct;142(20):1531-1534. doi: 10.1055/s-0043-103471. Epub 2017 Oct 10. German.

PMID:
29017211
41.

Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?

Ledur PF, Onzi GR, Zong H, Lenz G.

Oncotarget. 2017 Aug 11;8(40):69185-69197. doi: 10.18632/oncotarget.20193. eCollection 2017 Sep 15. Review.

42.

Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.

de Andrade Mello P, Bian S, Savio LEB, Zhang H, Zhang J, Junger W, Wink MR, Lenz G, Buffon A, Wu Y, Robson SC.

Oncotarget. 2017 Jun 21;8(40):67254-67268. doi: 10.18632/oncotarget.18595. eCollection 2017 Sep 15.

43.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. Erratum in: J Clin Oncol. 2018 Feb 10;36(5):521.

PMID:
28976790
44.

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A.

Leuk Lymphoma. 2018 May;59(5):1260-1263. doi: 10.1080/10428194.2017.1370546. Epub 2017 Sep 3. No abstract available.

PMID:
28868954
45.

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.

Kipper FC, Silva AO, Marc AL, Confortin G, Junqueira AV, Neto EP, Lenz G.

Invest New Drugs. 2018 Apr;36(2):323-331. doi: 10.1007/s10637-017-0503-7. Epub 2017 Aug 29.

PMID:
28852916
46.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

47.

NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin.

Melo-Hanchuk TD, Slepicka PF, Meirelles GV, Basei FL, Lovato DV, Granato DC, Pauletti BA, Domingues RR, Leme AFP, Pelegrini AL, Lenz G, Knapp S, Elkins JM, Kobarg J.

Sci Rep. 2017 Jul 14;7(1):5445. doi: 10.1038/s41598-017-05325-w.

48.

Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.

Salton GD, Laurino CCFC, Mega NO, Delgado-Cañedo A, Setterblad N, Carmagnat M, Xavier RM, Cirne-Lima E, Lenz G, Henriques JAP, Laurino JP.

Cancer Biol Ther. 2017 Aug 3;18(8):560-570. doi: 10.1080/15384047.2017.1345383. Epub 2017 Jul 10.

49.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
50.

Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.

Villodre ES, Kipper FC, Silva AO, Lenz G, Lopez PLDC.

Mol Neurobiol. 2018 May;55(5):4185-4194. doi: 10.1007/s12035-017-0611-6. Epub 2017 Jun 13.

PMID:
28612256

Supplemental Content

Support Center